4-[(2-Amino-acetylamino)-methyl]-benzoic acid | 51542-05-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-[(2-Amino-acetylamino)-methyl]-benzoic acid
• 英文别名: 4-[[(2-Aminoacetyl)amino]methyl]benzoic acid
• CAS: 51542-05-3
• 化学式: C₁₀H₁₂N₂O₃
• 分子量: 208.217
• InChiKey: RERRGJFDEMSIRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  92.4
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• GLYCINE COMPOUND
  申请人：Yoshihara Kousei

  公开号：US20120184520A1

  公开（公告）日：2012-07-19

  [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.

  本发明提供了一种化合物，该化合物可用作药物组合物的活性成分，特别是用于预防和/或治疗与VAP-1相关的疾病的药物组合物。 本发明的解决方案是，本发明者对具有VAP-1抑制活性的化合物进行了深入研究，结果发现本发明的化合物或其盐表现出优异的VAP-1抑制活性，并且对于预防和/或治疗与VAP-1相关的疾病，特别是糖尿病肾病或糖尿病黄斑水肿，具有用处，从而完成了本发明。本发明还涉及一种药物组合物，特别是用于预防和/或治疗与VAP-1相关的疾病的药物组合物，其包括本发明的化合物或其盐以及赋形剂。
• PANCREATIC ENDOCRINE CELL INDICATOR AND UTILIZATION OF SAME
  申请人：Riken

  公开号：EP2460542A1

  公开（公告）日：2012-06-06

  A pancreatic endocrine cell indicating agent of the present invention includes a modified polypeptide in which a metal chelator binds only to an amino acid that is located at a site other than a somatostatin receptor-binding active site in a polypeptide selected from the group consisting of somatostatin and somatostatin analogs; and a radioactive metal nuclide held by the metal chelator. According to the present invention, it is therefore possible to provide a novel pancreatic endocrine cell indicating agent.

  本发明的一种胰腺内分泌细胞指示剂包括一种改性多肽，其中的金属螯合剂仅与一个氨基酸结合，该氨基酸位于选自体生长抑素和体生长抑素类似物组成的组中的多肽中的体生长抑素受体结合活性位点以外的位点；以及由金属螯合剂保持的放射性金属核素。因此，根据本发明，可以提供一种新型胰腺内分泌细胞指示剂。
• PANCREATIC ENDOCRINE CELL INDICATING AGENT AND UTILIZATION OF SAME
  申请人：Watanabe Yasuyoshi

  公开号：US20120177571A1

  公开（公告）日：2012-07-12

  A pancreatic endocrine cell indicating agent of the present invention includes a modified polypeptide in which a metal chelator binds only to an amino acid that is located at a site other than a somatostatin receptor-binding active site in a polypeptide selected from the group consisting of somatostatin and somatostatin analogs; and a radioactive metal nuclide held by the metal chelator. According to the present invention, it is therefore possible to provide a novel pancreatic endocrine cell indicating agent.
• US8802679B2
  申请人：——

  公开号：US8802679B2

  公开（公告）日：2014-08-12
• [EN] COMBINED INHIBITORS OF CYCLOOXYGENASE AND SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) (VASCULAR ADHESION PROTEIN, VAP-1)<br/>[FR] INHIBITEURS COMBINÉS DE LA CYCLOOXYGÉNASE ET DE L'AMINE OXYDASE SENSIBLE AU SEMICARBAZIDE (SSAO) (PROTÉINE D'ADHÉSION VASCULAIRE, VAP-1)
  申请人：JOLLA PHARMA

  公开号：WO2009055002A1

  公开（公告）日：2009-04-30

  Compounds are disclosed which inhibit both semicarbazide-sensitive amine oxidase (SSAO) activity and cyclooxygenase (COX) activity. The compounds combine residues or pharmacophores of SSAO inhibitors with residues or pharmacophores of COX inhibitors in order to create the dual inhibitors. Methods of treatment of diseases, such as inflammation, are also disclosed.